Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

Case-Control Studies Humans *Polymorphism Single Nucleotide Promoter Regions Genetic Urinary Bladder Neoplasms/*genetics Vascular Endothelial Growth Factor A/*genetics Bladder cancer Meta-analysis Polymorphism Vascular endothelial growth factor competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

*DNA Methylation DNA Neoplasm/*metabolism Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*genetics Biomarker Bladder cancer DNA methylation Overall survival Progression-free survival

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Asymptomatic Diseases BCG Vaccine/*administration & dosage/adverse effects Bacteriuria/*complications/diagnosis Humans Immunotherapy/adverse effects/*methods Neoplasm Invasiveness Risk Assessment Treatment Outcome Urinary Bladder Neoplasms/complications/*drug therapy/immunology/pathology Bacillus Calmette-Guerin Bacteriuria Bladder cancer Intravesical instillation